Market Research Logo

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 6, 8, 11, 3 and 1 respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hospital Acquired Pneumonia (HAP) - Overview
Hospital Acquired Pneumonia (HAP) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
AstraZeneca Plc
Cardeas Pharma Corp
Centauri Therapeutics Ltd
CytaCoat AB
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Evaxion Biotech ApS
Lakewood-Amedex Inc
MedImmune LLC
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics plc
Polyphor AG
Sealife PHARMA GMBH
Shionogi & Co Ltd
Tetraphase Pharmaceuticals Inc
Theravance Biopharma Inc
Wockhardt Ltd
Zavante Therapeutics Inc
Hospital Acquired Pneumonia (HAP) - Drug Profiles
(amikacin + fosfomycin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(avibactam + aztreonam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
((avibactam + ceftazidime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + zidebactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cilastatin sodium + imipenem + relebactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aerucin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alalevonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbekacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cefiderocol sulfate tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVXB-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exeporfinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iclaprim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levonadifloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-3902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
murepavadin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NU-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Panaecin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
panobacumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
POL-7001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharides for Hospital Acquired Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Qn-2251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Bacterial Infections and Ventilator Associated Pneumonia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
suvratoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telavancin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tosatoxumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZTI-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hospital Acquired Pneumonia (HAP) - Dormant Projects
Hospital Acquired Pneumonia (HAP) - Discontinued Products
Hospital Acquired Pneumonia (HAP) - Product Development Milestones
Featured News & Press Releases
Jun 06, 2018: Shionogi Announces Upcoming Presentations on Cefiderocol at American Society for Microbiology Microbe Meeting
May 09, 2018: Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development
Feb 01, 2018: FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Feb 01, 2018: FDA Approves AVYCAZ (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Jan 15, 2018: Pfizer’s Zavicefta Rejects For Use Within NHS Scotland
Jan 15, 2018: Pfizer’s Zavicefta Rejects for Use within NHS Scotland
Oct 04, 2017: Allergan To Present New Data on AVYCAZ At IDWeek 2017 In San Diego
Oct 04, 2017: Allergan To Present New Data on AVYCAZ At IDWeek 2017 In San Diego
Apr 24, 2017: Pivotal Phase III Study Underscores Efficacy Of Zavicefta (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals
Apr 19, 2017: Merck to Present Data on ZERBAXA at ECCMID
Oct 31, 2016: New Data On Iclaprim Released At Idweek 2016; Iclaprim Shown To Be Highly Potent Against SSSI And HABP Clinical Isolates
Oct 31, 2016: Theravance Biopharma Presents Interim Data from Ongoing Telavancin Observational Use Registry (TOUR) at IDWeek
Jul 21, 2016: AstraZeneca's antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Centauri Therapeutics Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by CytaCoat AB, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Evaxion Biotech ApS, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics plc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor AG, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2018
Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2018
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2018
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report